1. Aaronson, N., Ahmedzai, S., Bergmann, B., Bullinger, M., Cull, A., Duez, N., de Haes, J. (March 1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 5(85), 365-376.
2. Ahmed, K., Marchand, E., Williams, V., Coscarelli, A., & Ganz, P. (März 2016).
Development and pilot testing of a psychosocial intervention program for young breast cancer survivors. Patient education and counseling., 99(3), 414-420.
3. Arès, I., Lebel, S., & Bielajew, C. (2014). The impact of motherhood on perceived stress, illness intrusiveness and fear of cancer recurrence in young breast cancer survivors over time. Psychology & health., 651-70.
4. AWMF. (2017). Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinienprogramm Onkologie | Kurzversion S3-Leitlinie Mammakarzinom Version 4.0 November 2017, S. 40.
5. Beesley, V., Alemayehu, C., & Webb, P. (2018). A systematic literature review of the prevalence of and risk factors for supportive care needs among women with gynaecological cancer and their caregivers. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer., 701-710.
6. Bermejo-Perez, M., Marquez-Calderon, S., & Llanos-Mendez, A. (2007).
Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. International Journal of Cancer, 121(2), S. 225-231.
7. Blichert-Toft, M., Smola, M., Cataliotti, L., & O'Higgins, G. (1998). Annales chirurgiae et gynaecologiae, 87(1), S. 101-109.
8. Brennan, M., Butow, P., Spillane, A., & Boyle, F. (2016). Patient-reported quality of life, unmet needs and care coordination outcomes: Moving toward targeted breast cancer survivorship care planning. Asia-Pacific journal of clinical oncology, 323-331.
9. Butow, P., Bell, M., Smith, A., Fardell, J., Thewes , B., Turner, J.,Sharpe, L.
(2013). Conquer fear: protocol of a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence. BMC cancer., 201.
10. Carroll, B., Kathol, R., Noyes, R., Wald, T., & Clamon, G. (1993). Screening for depression and anxiety in cancer patients using Hosptal Anxiety and Depression Scale. General Hospital Psychiatry, 69-74.
11. Cho, D., Chu, Q., & Lu, Q. (2017). Associations among physical symptoms, fear of cancer recurrence, and emotional well-being among Chinese American breast cancer survivors: a path model. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer., doi: 10.1007/s00520-017-4010-3. [Epub ahead of print].
55
12. Christiaens, M., Vlayen, J., & Gailly, J. (2007). Scientific support of the College of Oncology: a national clinical practice guideline for breast cancer. Brüssel:
Belgian Health Care Knowledge Centre.
13. Costanzo, E., Lutgendorf , S., Mattes, M., Trehan, S., Robinson , C., Tewfik , F.,
& Roman, S. (2007). Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. British journal of cancer, 1625-31.
14. Crist, J., & Grunfeld, E. (22. May 2013). Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psychooncology(5), S. 978-86.
15. Dankert, A., Duran, G., Engst-Hastreiter, U., Keller, M., Waadt, S., Heinrich, G.,
& Herschbach, P. (2003). Progredienzangst bei Patienten mit Tumorerkrankungen, Diabetes mellitus und entzündlich-rheumatischen Erkrankungen. Rehabilitation(42), S. 155-163.
16. Davies, C., Godwin, J., Pan, H., Arriagada, R., Raina, V., Abraham, M., Peto, R.
(March 2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet, 381(9), S. 805-816.
17. Department of Health. (2015). National Clinical Guideline - Diagnosis, staging and treatment of patients with Breast Cancer. National Clinical Giudeline No.7.
18. Dumitrescu, R., & Cotarla, I. (10. Dezember 2005). Understanding breast cancer risk - where do we stand in 2005? Journal of Cellular and Molecular Medicine, 9(1), S. 208-221.
19. EBCTC, & Group, E. B. (1995). Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. England Journal of Medicine, 333(22), S. 1444-1455.
20. Edwards, A. (1959). The Social Desirability Variable in Personality Research.
Journal of the American Statistical Association 54(285).
21. Ellegaard, M., Grau, C., Zachariae, R., & Blonde Jensen, A. (2017). Fear of cancer recurrence and unmet needs among breast cancer survivors in the first five years. A cross-sectional study. Acta oncologica., 314-320.
22. Engst-Hastreiter, U., Henrich, G., & Duran, G. (2003). Belastungsscreening und Bedarfsanalyse psychosozialer Unterstützung bei chronischen Erkrankungen (Rheuma, Krebs) in der stationären Rehabilitation am Beispiel von Progredienzangst (PA). DRV-Schriften(40), S. 234-236.
23. Fayers, P., Aaronson, N., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A.(2001). The EORTC QLQ-C30 Scoring Manual (3rd Edition).
24. Fisher, B., & Anderson, S. (1994). Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National
56
Surgical Adjuvant Breast and Bowel Project. World Journal of Surgery, 18(1), S.
63-69 .
25. Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V.,Liberati, A. (1998). Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. Journal of Clinical Oncology, 16(10), 3439-3460.
26. Ganz, P. (2001). Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. Journal of the National Cancer Institute. Monographs., 130-134.
27. Ganz, P. (2008). Psychological and social aspects of breast cancer. Oncology, 642-6, 650; discussion 650, 653.
28. Ganz, P., Kwan, L., Stanton, A., Bower, J., & Belin, T. (2011). Physical and psychosocial recovery in the year after primary treatment of breast cancer.
Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 1101-9.
29. Geller, B., Kerlikowske, K., Carney, P., Abraham, L., Yankaskas, B., Taplin, S., Barlow, W. (2003). Mammography surveillance following breast cancer. Breast Cancer Research and Treatment, 81(2), S. 107-115 .
30. Hall, D., Mishel, M., & Germino, B. (2014). Living with cancer-related uncertainty:
associations with fatigue, insomnia, and affect in younger breast cancer survivors. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer., 2489-95.
31. Hammond, M., Hayes, D., Dowsett, M., Allred, D., Hagerty, K., Badve, S., Pathologists, C. o. (July 2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). 134(7), S. 48-72.
32. Hanprasertpong , J., Geater, A., Jiamset , I., Padungkul , L., Hirunkajonpan , P.,
& Songhong, N. (2017). Fear of cancer recurrence and its predictors among cervical cancer survivors. Journal of gynecologic oncology, doi:10.3802/jgo.2017.28.e72.
33. Hartmann, L., Sellers, T., Frost, M., Lingle, W., Degnim, A., Ghosh, K.,Visscher, D. (2005). Benign breast disease an d the risk of breast cancer. New England Journal of Medicine, 353(3), S. 229-237.
34. Helgeson, V., & Tomich, P. (2005). Surviving cancer: a comparison of 5-year disease-free breast cancer survivors with healthy women. Psychooncology, 307-17.
57
35. Herrman, C. (1997). International Experiences with the Hospital Anxiety and Depression Scale: a Review of Validation Data and clinical results. Journal of Psychosomatic Research, 17-41.
36. Herrmann, C., Buss, U., & Snaith, R. P. (1995). HADS-D Hospital Anxiety and Depression Scale-Deutsche Version (1. Auflage Ausg.). Bern: Verlag Hans Huber.
37. Herschbach, P., & Dinkel, A. (2014). Fear of Progression. Recent results in cancer research., S. 11-29.
38. Herschbach, P., Berg, P., Dankert, A., Duran, G., Engst-Hastreiter, U., Waadt, S.,Heinrich, G. (June 2005). Fear of progression in chronic diseases:
psychometric properties of the Fear of Progression Questionnaire. Journal of psychosomatic research, S. 505-11.
39. Herschbach, P., Berg, P., Waadt, S., Duran, G., Engst-Hastreiter , U., Henrich, G.,Dinkel, A. (2010). Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis or cancer. Psychotherapy and psychosomatics., 31-38.
40. Hill, J., Holcombe , C., Clark, L., Boothby, M., Hincks, A., Fisher, J.,Salmon, P.
(2011). Predictors of onset of depression and anxiety in the year after diagnosis of breast cancer. Psychological medicine., 1429-36.
41. Hinz, A., Mehnert , A., Ernst, J., Herschbach, P., & Schulte, T. (2015). Fear of progression in patients 6 months after cancer rehabilitation-a- validation study of the fear of progression questionnaire FoP-Q-12. Supportive Care in Cancer:
official journal of the Multinational Association of Supportive Care in Cancer., 1579-87.
42. Kast, K., & Rhiem, K. (2013). Komme ich aus einer Krebsfamilie? Informationen für Männer und Frauen zum familiären Brust- und Eierstockkrebs. GeKo Verlag GbR.
43. Khatcheressian, J., Wolff, A., Smith, T., Grunfeld, E., Muss, H., Vogel, V., Davidson, N. (2006). American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.
Journal of Clinical Oncology, 24(31), S. 5091-5097.
44. King, M., Kenny, P., Shiell, A., Hall, J., & Boyages , J. (2000). Quality of life three months and one year after first treatment for early stage breast cancer: influence of treatment and patient characteristics. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation., 789-800.
45. Koch, L., Bertram, H., Eberle, A., Holleczek , B., Schmid-Höpfner, S., Waldmann, A., Arndt , V. (2014). Fear of recurrence in long-term breast cancer survivors-still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship--a multi-regional population-based study. Psychoncology, 547-54.
58
46. Koch, U., & Beutel, M. (1988). Psychische Belastungen und Bewältigungsprozesse bei Krebspatienten. In U. Koch, G. Lucius-Hoene, & R.
(Stegie, Handbuch der Rehabilitationspsychologie (S. 397-434). Berlin Heidelberg: Springer Verlag.
47. Koch-Gallenkamp, L., Bertram, H., Eberle, A., Holleczek, B., Schmid-Höpfner, S., Waldmann, A., Arndt, V. (12. May 2016). Fear of Recurrence in Long-Term Cancer Survivors-Do Cancer Type, Sex, Time Since Diagnosis, and Social Support matter? Health Psychology, S. 1329-1333.
48. Konsortium familiärer Brust- und Eierstockkrebs. (Juli 2012). Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms.
AWMF.
49. Kuehn, T., Bembenek, A., Decker, T., Munz, D., Sautter-Bihl, M., Untch, M., &
Wallwiener, D. (2005). A concept for the clinical implementation of sentinel lymphnode biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer, 103(3), S. 451-461.
50. Lakhani, S. (2003). In-situ lobular neoplasia: time for an awakening. Lancet, 361(9352), S. 96.
51. Last, J. M. (2000). A Dictionary of Epidemiology. Oxford University Press.
52. Lavrakas, P. J. (10. März 2018). Encyclopedia of Survey Research Methods. Von
http://methods.sagepub.com/reference/encyclopedia-of-survey-research-methods/n448.xml abgerufen
53. Lebel, S., Beattie, S., Arès , I., & Bielajew, C. (2013). Young and worried: Age and fear of recurrence in breast cancer survivors. Health Psychology, 695-705.
54. Lebel, S., Maheu, C., Lefebvre , M., Secord, S., Courbasson, C., Singh, M., Catton , P. (2014). Addressing fear of cancer recurrence among women with cancer: a feasibility and preliminary outcome study. Journal of cancer survivorship: research and practice., 485-96.
55. Lebel, S., Ozakinci, G., Humphris , G., Thewes, B., Prins, J., Dinkel, A., & Butow, P. (2017). Current state and future prospects of research on fear of cancer reccurrence. Psychooncology, 424-427.
56. Lebel, S., Rosberger, Z., Edgar, L., & Devins, G. (2009). Emotional distress impacts fear of the future among breast cancer survivors not the reverse. Journal of Cancer survivorship: research and practice., 117-27.
57. Lee, K., Janz, N., Zikmund-Fisher, B., Jagsi , R., Wallner , L., Kurian , A., Hawley , S. (2017). What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment? Medical decision making: an international journal of the Society of Medical Decision Making., 95-106.
59
58. Levine, M. (2001). Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). Canadian Medical Association Journal, 7(165).
59. Liu, Y., Perez , M., Shootman, M., Aft, R., Gillanders, W., & Jeffe, G. (2011).
Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. Breast cancer research and treatment., 165-73.
60. Lostumbo, L., Carbine, N., & Wallace, J. (2010). Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010, S.
(11):CD002748.
61. Maheu, C., Lebel, S., Courbasson, C., Lefebvre, M., Singh, M., Bernstein, L., Sidani, S. (2016). Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer. BMC cancer., 291.
62. McPherson, K., Steel, C. M., & Dixon, J. M. (9. September 2000). ABC of breast diseases-Breast cancer—epidemiology, risk factors, and genetics. British Medical Journal, S. 624-628.
63. Mehnert, A., & Koch, U. (2008). Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. Journal of Psychosomatic research., 383-91.
64. Mehnert, A., Berg, P., Henrich, G., & Herschbach, P. (2009). Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors.
Psychoncology, 1273-80.
65. Mehnert, A., Herschbach, P., Berg, P., Heinrich, G., & Koch, U. (2006). Fear of progression in breast cancer patients-validation of the short form of the Fear of Progression Questionnaire (FoP-Q-SF). Zeitschrift für Psychosomatische Medizin und Psychotherapie, 3(52), S. 274-88.
66. Mehnert, A., Herschbach, P., Berg, P., Heinrich, G., & Koch, U. (2006). Fear of progression in breast cancer patients--validation of the short form of the Fear of Progression Questionnaire (FoP-Q-SF). 3(52), S. 274-288.
67. Mehnert, A., Koch, U., Sundermann, C., & Dinkel, A. (2013). Predictors of fear of recurrence in patients one year after cancer rehabilitation: A prospective study.
Acta Oncologica, 1102-1109.
68. National Institute for Clinical Excellence (NICE). (2009b). Early and locally advanced breast cancer: diagnosis and treatment.
69. Ozga, M., Aghajanian, C., Myers-Virtue, S., McDonnell, G., Jhanwar, S., Hichenberg, S., & Sulimanoff, I. (2. März 2015). A systematic review of ovarian cancer and fear of recurrence. Palliative & Supportive Care., 13(6), 1771-1780.
60
70. Prien, P. (2. September 2015). Onko-Internetportal der Deutschen Krebsgesellschaft. Abgerufen am 25. August 2016 von
https://www.krebsgesellschaft.de/onko-internetportal/basis-informationen-krebs/krebsarten/brustkrebs/tumorbiologie.html
71. Robert Koch Institut. (November 2016). Bericht zum Krebsgeschehen in Deutschland 2016. Zentrum für Krebsregisterdaten.
72. Robert Koch Institut. (2017). Krebs in Deutschland 2013/2014. S. 72-77.
73. Robinson, E., Kimmick, G., & Muss, H. (1996). Tamoxifen in postmenopausal women a safety perspective. Drugs & aging. , 329-37.
74. Rojas, M., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., Liberati, A.
(2005). Cochrane Database Syst Rev 2005, S. (1):CD001768.
75. Salander, P. (2010). Motives that cancer patients in oncological care have for consulting a psychologist--an empirical study. Psychoncology., 248-254.
76. Schmutzler, & Schmidt. (2015). Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Guidelines Breast Version 2015.1D.
AGO-Leitlinie.
77. Schwarz, R. (1996). Angst und Depressionen bei Krebskranken. 2, 582-592.
78. Schwarz, R., & Hinz, A. (July 2001). Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. European Journal of Cancer, 11(37), S. 1345-51.
79. Sekse, R., Raaheim, M., Blaaka, G., & Giengedal, E. (2010). Life beyond cancer:
women's experiences 5 years after treatment for gynaecological cancer.
Scandinavian Journal of caring sciences., 799-807.
80. Simard, S., Thewes, B., Humphris, G., Dixon, M., Hayden, C., Mireskandari, S.,
& Ozakinci, G. (September 2013). Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. Journal of cancer survivorship: research and practice., S. 300-22.
81. Singer, S., Bringmann, H., Hauss, J., Kortmann, R., Köhler, U., Krauss, O., &
Schwarz, R. (2007). Häufigkeit psychischer Begleiterkrankungen und der Wunsch nach psychosozialer Unterstützung bei Tumorpatienten im Akutkrankenhaus,. Deutsche Medizinische Wochenschrift, 132(40), S. 2071-2076.
82. Snyder, K., & Pearse, W. (2010). Crisis, Social Support, and the Family Response: Exploring the Narratives of Young Breast Cancer Survivors. Journal of Psychosocial Oncology, 413–431.
83. Söllner, W., Zschocke, I., Zingg-Schir, M., Stein, B., Rumpold, G., Fritsch, P., &
Augustin, M. (1999). Interactive patterns of social support and individual coping
61
strategies in melanoma patients and their correlations with adjustment to illness.
Psychosomatics., 239-50.
84. Sprangers, M., Groenvold, M., Arraras, J., Franklin, J., te Velde, A., Muller, A., Aaronson, N. (October 1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module:
first results from a three-country field study. Journal of clinical oncology, 10(14), S. 2756-68.
85. Stava, C., Lopez, A., & Vassilopoulou-Sellin , R. (2006). Health profiles of younger and older breast cancer survivors. Cancer, 1752-9.
86. Thewes, B., Brebach, R., Dzidowska, M., Rhodes, P., Sharpe, L., & Butow, P.
(2014). Current approaches to managing fear of cancer recurrence; a descriptive survey of psychosocial and clinical health professionals. Psychooncology., 390-6.
87. Thompson, D., Spanier, C., & Vogel, V. (1999). The Relationship Between Tamoxifen, Estrogen, and Depressive Symptoms. The breast journal., 375-382.
88. UICC. (2010). deutsche Übersetzung von Wittekind und Mayer 7. Auflage.
Weinheim: Wiley-VCH-Verlag GmBH und co. KGA.
89. van den Beuken-van Everdingen, M., Peters, M., de Rijke , J., Schouten , H., van Kleef , M., & Patijn , J. (2008). Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology, 1137-45.
90. van Helmondt, S., van der Lee, M., & de Vries, J. (2016). Study protocol of the CAREST-trial: a randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with curatively treated breast cancer. BMC cancer., 527.
91. Waadt, S., Duran, G., Berg, P., & Herschbach, P. (2011). Progredienzangst.
Manual zur Behandlung von Zukunftsängsten bei chronisch Kranken. Stuttgart:
Schattauer.
92. Wenzel, L., Fairclough, D., Brady, M., Cella, D., Garrett, K., Kluhsman, B., Marcus, A. (1999). Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer., 1768-74.
93. Willems, R., Bolman, C., Mesters , I., Kanera , I., Beaulen, A., & Lechner, L.
(2016). Cancer survivors in the first year after treatment: the prevalence and correlates of unmet needs in different domains. Psychooncology, 51-7.
94. Zebrack , B., Yi, J., Petersen, L., & Ganz, P. (2008). The impact of cancer and quality of life for long-term survivors. Psychooncology, 891-900.
62